Actively Recruiting
Assessment of Cardiac Function, Microvascular Function and Cardiac Perfusion in Different Disease Stages of Hypertrophic Cardiomyopathy
Led by Amsterdam UMC, location VUmc · Updated on 2024-05-06
100
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Hypertrophic cardiomyopathy (HCM) is a genetic disorder characterized by asymmetric hypertrophy of the heart in absence of loading conditions like hypertension. The genetic mutation underlying HCM sets in motion a cascade of functional and metabolic changes ultimately leading to disease. HCM patients often have microvascular dysfunction and myocardial perfusion deficits, of which the aetiology has not been elucidated. Whether these changes are secondary to remodelling or primarily caused by endothelial dysfunction is unclear. As the pathomechanism of HCM is thought to be a cascade of changes, it is important to gain more insight in the perfusion and endothelial function changes throughout different stages of disease: no phenotype, mild phenotype, and advanced HCM phenotype. In this study we aim to investigate these changes in the two most common genetic mutations.
CONDITIONS
Official Title
Assessment of Cardiac Function, Microvascular Function and Cardiac Perfusion in Different Disease Stages of Hypertrophic Cardiomyopathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Must be a MYBPC3 or MYH7 mutation carrier, or a genotype-negative first-degree relative of such a carrier
- Mutation carriers must be 18 years or older
- Genotype-negative relatives must be 30 years or older
- Mutation carriers will be classified into groups based on maximum heart wall thickness: no phenotype (less than 12 mm), mild phenotype (12 to less than 15 mm), or HCM phenotype (15 mm or more)
You will not qualify if you...
- Age over 70 years
- Insulin-dependent diabetes mellitus
- Pregnancy
- Smoking
- Claustrophobia
- Having a pacemaker or implantable cardioverter-defibrillator (ICD)
- Renal insufficiency with glomerular filtration rate below 30
- Hypertension with systolic blood pressure over 140 mmHg or diastolic over 90 mmHg
- Use of blood pressure medication for genotype-negative, no phenotype, and mild phenotype groups
- For HCM phenotype group, inability to safely stop blood pressure medication for two days
- Left ventricular outflow tract gradient over 50 mmHg
- Aortic valve disease
- Left bundle branch block
- History of obstructive coronary artery disease
- Chronic atrial fibrillation
- Hormone replacement therapy
- Second or third-degree AV-block, sick sinus syndrome, or prolonged QT interval
- Asthma or other obstructive lung diseases
- Previous adverse reaction to adenosine or dotarem
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Amsterdam UMC - location VUmc
Amsterdam, North Holland, Netherlands, 1081HV
Actively Recruiting
Research Team
J
Julia E Visch, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here